ASP-1570: An Investigational DGKZ Inhibitor for Cancer Immunotherapy

1. Introduction to ASP-1570

ASP-1570 (also referred to as ASP1570 or ASP 1570) is an investigational therapeutic agent currently under clinical development for the treatment of cancer.[1] It originated from and is being developed by Astellas Pharma Inc., a global pharmaceutical company.[1] The discovery of ASP-1570 was a collaborative effort between Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd., highlighting potential partnerships in its early genesis.[5]

Chemically, ASP-1570 is classified as a small molecule drug.[1] This modality often allows for oral administration, potentially offering greater patient convenience compared to intravenously delivered biologics. It is designated as a New Molecular Entity (NME), signifying that its active component has not been previously approved by regulatory authorities like the FDA.[1] Therapeutically, ASP-1570 falls under the class of Antineoplastics [1] and is specifically being investigated within the rapidly evolving field of cancer immunotherapy, or immuno-oncology.[5]

The primary molecular target of ASP-1570 is Diacylglycerol Kinase Zeta (DGKZ, also denoted DGKζ).[1] Consequently, ASP-1570 functions mechanistically as a DGKZ protein inhibitor.[1] This mechanism is considered novel in the context of cancer therapy.[4] The intended route of administration for ASP-1570 is oral, typically as tablets taken once or twice daily.[3]